EDIT - Editas Medicine Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
2024-03-13 19:58:04 ET
Editas Medicine, Inc. (EDIT)
Barclays 26th Annual Global Healthcare Conference
March 13, 2024 02:05 PM ET
Company Participants
Gilmore O'Neil - Chief Executive Officer
Erick Lucera - Chief Financial Officer
Conference Call Participants
Gena Wang - Barclays
Presentation
Gena Wang
Good afternoon, everyone, and welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover the US mid-cap biotech. It is my great pleasure to introduce our next presenting company, Editas Medicine. With us today we have Gilmore O'Neil, Chief Executive Officer; we also have Erick Lucera, Chief Financial Officer.
Before I dive into specific questions, Gilmore, maybe you wanted to give them a bit high-level overview of Editas.
Gilmore O'Neil
Yes. Thank you. Thanks very much, Gena. Very nice to be here. So Editas is a genome at CRISPR based editing company. We have a three core pillars to our strategy. We are driving our lead clinical asset reni-cel, a CRISPR edited a Cas12a edited cell-based therapy for sickle cell disease thalassemia, which would drive through the clinic. And I can tell you more about that in a moment....
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)